Yahoo Finance • 3 months ago
Many investors rightfully identify biotech stocks as being riskier than average, and those stocks certainly have a habit of earning their reputation. Still, there are a few up-and-coming biotechs that have revenue and a clear path to gener... Full story
Yahoo Finance • 6 months ago
Iovance Biotherapeutics, Inc. Lifileucel TIL Cell Therapy in Combination with Pembrolizumab Demonstrates Deep, Durable Responses in Frontline Advanced Melanoma Patients in IOV-COM-202 Clinical Study ASCO Oral Presentation to Highlight 65... Full story
Yahoo Finance • 6 months ago
Iovance Biotherapeutics(NASDAQ: IOVA) shares are down to the tune of 18% today following Thursday evening's release of its first-quarter numbers. The sell-off clearly suggests investors didn't like everything they heard. The knee-jerk resp... Full story
Yahoo Finance • 7 months ago
They're often grouped together, but not all growth stocks are the same. Indeed, they're each dramatically different in terms of risk, potential, and longevity. One's not inherently as good as another. With that as the backdrop, here's a c... Full story
Yahoo Finance • 7 months ago
It's been a tough past three years for biotech stocks. Although the COVID-19 pandemic sparked bullish interest in the industry, this interest has waned since the contagion began winding down. Between late 2021 and now, the Nasdaq Biotechno... Full story
Yahoo Finance • 9 months ago
Some investors are attracted to small biotech stocks because of their potential for explosive returns. It's not uncommon for these stocks to go parabolic after positive news is announced. That's exactly what happened to Iovance Biotherape... Full story
Yahoo Finance • 9 months ago
With shares of Iovance Biotherapeutics (NASDAQ: IOVA) soaring by 175% in the last three months, Wells Fargo analyst Yanan Zhu thinks they could still go as much as 47% higher. In fact, on Feb. 20, the analyst raised his price target for th... Full story
Yahoo Finance • 9 months ago
In this piece, we will take a look at the 13 best short squeeze stocks to buy now. If you want to skip our primer on short squeezing, and some of the greatest short squeezes in history, then you can take a look at the 5 Best Short Squeeze... Full story
Yahoo Finance • 9 months ago
Shares of Iovance Biotherapeutics(NASDAQ: IOVA) had skyrocketed by 33.8% as of 10:39 a.m. ET Tuesday. The huge gain came after the company announced on Friday that the Food and Drug Administration (FDA) had granted accelerated approval for... Full story
Yahoo Finance • 9 months ago
Iovance Biotherapeutics, Inc. SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel... Full story
Yahoo Finance • 11 months ago
The FDA places a clinical hold on Iovance’s trial of a lung cancer therapy after the company reports a death potentially related to the treatment. Continue reading... Full story
Yahoo Finance • 11 months ago
It isn't over yet, but 2023 has given Wall Street a lot more to be excited about than 2022 did. Signs of a soft landing for the U.S. economy have pushed the S&P 500 index up nearly 20% this year. The benchmark index is up sharply this yea... Full story
Yahoo Finance • last year
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were jumping 10.9% higher as of 11:49 a.m. ET on Monday. The nice gain came after Goldman Sachs initiated coverage on Iovance stock with a buy recommendation. Investors no doubt liked Goldma... Full story
Yahoo Finance • last year
ARK Investment Management's Latest 13F Filing Highlights Key Stock Movements Renowned for her focus on disruptive innovation, Catherine Wood (Trades, Portfolio), the founder and CEO of ARK Investment Management, has made notable changes t... Full story
Yahoo Finance • last year
FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act Action (PDUFA) Date of February 24, 2023 Positive Regulatory Feedback Supports Lifileucel Regulato... Full story
Yahoo Finance • last year
SAN CARLOS, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies... Full story
Yahoo Finance • last year
STAMFORD, Conn., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”) on behalf of the Company’s investors to determine whether Iovance’s board of... Full story
Yahoo Finance • last year
SAN CARLOS, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies... Full story
Yahoo Finance • last year
Priority Review Continues with Successful Facility Inspections Completed, no Major Review Issues FDA Extends PDUFA Date to February 24, 2024 on Resource Constraints and Agrees to Work with Iovance to Expedite Remaining Review SAN CARLOS,... Full story
Yahoo Finance • last year
SAN CARLOS, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies... Full story